Virtus Fund Advisers’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q4
$5.73M Sell
166,769
-4,314
-3% -$147K 0.06% 226
2017
Q3
$5.79M Sell
171,083
-18,296
-10% -$588K 0.06% 226
2017
Q2
$5.99M Sell
189,379
-1,287,583
-87% -$40.6M 0.06% 241
2017
Q1
$47.9M Sell
1,476,962
-589,815
-29% -$18.6M 0.45% 97
2016
Q4
$63.7M Buy
2,066,777
+61,272
+3% +$1.87M 0.54% 61
2016
Q3
$64.4M Sell
2,005,505
-630,970
-24% -$21.1M 0.57% 57
2016
Q2
$89M Sell
2,636,475
-2,190,434
-45% -$69.9M 0.79% 34
2016
Q1
$136M Buy
4,826,909
+1,209,667
+33% +$34.6M 1.2% 9
2015
Q4
$111M Sell
3,617,242
-224,621
-6% -$7.07M 0.98% 25
2015
Q3
$114M Buy
3,841,863
+36,751
+1% +$1.18M 1% 23
2015
Q2
$121M Sell
3,805,112
-66,186
-2% -$2.16M 0.9% 23
2015
Q1
$128M Sell
3,871,298
-172,572
-4% -$5.49M 0.96% 21
2014
Q4
$120M Buy
4,043,870
+455,424
+13% +$13.1M 0.88% 24
2014
Q3
$101M Sell
3,588,446
-59,588
-2% -$1.67M 0.77% 30
2014
Q2
$103M Buy
+3,648,034
New +$104M 0.72% 24

Other funds holding PFE

Virtus Fund Advisers's PFE Position: Q4 2017 in Review

Virtus Fund Advisers reduced its Pfizer (PFE) stake by 2.5% in Q4 2017, selling an estimated $147K and leaving 166,769 shares worth $5.73M. The position accounts for 0.06% of the portfolio, ranked #226.

Virtus Fund Advisers first reported a position in PFE in Q2 2014 and has held it in 15 quarters since. The position peaked at $136M in Q1 2016. 2,244 funds tracked by Wall St. Rank hold PFE as of Q4 2017.

  • Virtus Fund Advisers held 166,769 shares of Pfizer worth $5.73M as of Q4 2017.
  • Virtus Fund Advisers sold 4,314 Pfizer shares in Q4 2017, an estimated $147K.
  • Pfizer made up 0.06% of Virtus Fund Advisers's portfolio in Q4 2017, its #226 holding.
  • Virtus Fund Advisers first reported a position in Pfizer in Q2 2014 and has held it in 15 quarters since.
  • Virtus Fund Advisers's Pfizer position peaked at $136M in Q1 2016.
  • 2,244 funds tracked by Wall St. Rank held Pfizer as of Q4 2017.

Based on Virtus Fund Advisers's 13F filing for Q4 2017, filed 9 Feb 2018.